3 "Strong Buy" Healthcare Stocks Under $5 That Could Go Boom
High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
Eli Lilly to continue other Covid-19 antibody drug trials after pausing one on safety concerns
MRNA Stock Price Pushes Higher On News COVID-19 Vaccine Works For Seniors
Careology teams up with private GP group on COVID-19 monitor
Inovio: Despite COVID-19 Vaccine Headwinds, Core Value Drivers Remain Intact, Says 5-Star Analyst
Cardiac arrest, poor survival rates common in sickest patients with COVID-19
Oxford to study anti-inflammatory drug Humira as potential Covid-19 treatment
Coronavirus: how the pharma industry is changing to produce a vaccine on time
BARDA boosts the fight against antibiotic-resistant infections with $144M awards
Regeneron Up 4% As Covid-19 Cocktail Lowers Viral Levels; Analyst Says Hold
InflaRx Pops 6% On ‘Promising’ Data From Covid-19 Therapeutic Trial
New research provides clues on optimizing cell defenses when viruses attack
Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%
Tesla's Nevada Gigafactory Has The County's Highest COVID-19 Case-Count Since June
Common antioxidant enzyme may provide potential treatment for COVID-19
Pfizer Nabs US Approval For Children's Oral Arthritis Drug
Computer model shows how COVID-19 could lead to runaway inflammation
Evergreen Gavekal: Investors' Guide To The 2020 Election
Research on emerging COVID-19 (target, mechanism, and therapeutics)
Thousands of excess deaths from cardiovascular disease during the COVID-19 pandemic
Digital technologies will help build resilient communities after the coronavirus pandemic
Pandemic sets off future wave of worsening mental health issues
These 2 Penny Stocks Are Poised for a Massive Rally, Says Roth Capital
RNA for Medical Analysis
A Primer For The Media On Viruses, Vaccines, & COVID-19
Is Sorrento Stock a Buy Right Now? This Is What You Need to Know
Global COVID-19 Deaths On Track To Top 1 Million, UK Prepares New 'Localized Lockdown' Measures: Live Updates
Valirx eyes partnerships as first VAL201 study hits the mark
Aquestive Plunges 37% As FDA Rejects Seizure Drug; Street Stays Bullish